RxDoctor Payments Data

Poorna Nalabothu, MD

Advanced Heart Failure and Transplant Cardiology · Salt Lake City, UTNPI 1538390869

Payments from drug & device makers

$18,450in general payments, 2019–2025

Across 655 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • Abiomed$1K
  • Cvrx, Inc.$1K
  • Pfizer$950
  • plus $7K from 30 others

What the payments were for

  • Travel & lodging$4,53325%
  • Food & beverage$13,88875%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$228,240
Medicare patients
1,451
Services billed
3,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis14$362,694
EliquisApixaban297$332,052
AdempasRiociguat16$225,403
OpsumitMacitentan16$207,117
EntrestoSacubitril/Valsartan191$201,086
CamzyosMavacamten23$183,764
FarxigaDapagliflozin Propanediol163$166,528
XareltoRivaroxaban46$49,833
JardianceEmpagliflozin22$24,367
Sildenafil Citrate25$10,335
Repatha SureclickEvolocumab18$9,478
Midodrine Hcl65$7,283
Metoprolol Succinate319$3,860
Amiodarone Hcl193$3,044
Potassium Chloride204$2,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$950$694,747311 claims
BayerAdempas$407$225,40316 claims
Actelion Pharmaceuticals US, Inc.Opsumit$546$207,11716 claims
NovartisEntresto$793$201,086191 claims
E.r. Squibb & Sons, L.L.C.Camzyos$771$183,76423 claims
AstraZenecaFarxiga$172$166,528163 claims
Johnson & JohnsonXarelto$886$49,83346 claims
Boehringer IngelheimJardiance$273$24,36722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Utahon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Salt Lake City

Where these figures come from

Is this you, or does something look wrong? →